A 12-Veteran Psilocybin Pilot Adds an Early PTSD Treatment Signal
A 12-person open-label pilot found large one-month PTSD symptom reductions after an intensive psilocybin-assisted therapy protocol. With no control group, the study cannot determine how much change came from the drug, preparation, therapeutic support, expectancy, selection or time.
Published July 30, 2026, in Communications Medicine, the single-site study followed 12 U.S. military veterans with severe PTSD that had persisted after prior medication and psychotherapy. It is the first published psilocybin-assisted therapy treatment report in this narrow veteran population and updates the literature-status statement in EMDRNews’s July 16 coverage.
What participants received
The intervention was not a stand-alone dose. Participants completed about eight hours of preparation with two facilitators, two day-long dosing sessions separated by two to three weeks, and four integration sessions totaling approximately six to eight hours. Medical monitoring, rescue medication and transportation support were built into the dosing days.
Symptoms had already declined during the preparation period before the first dose. That detail, along with the open-label design, makes it impossible to separate the effects of psilocybin from the unusually intensive care context.
What the study reported
Mean clinician-rated PTSD severity on the CAPS-5 fell from 39.67 at baseline to 12.17 one month after the second dosing session, a mean reduction of 27.5 points. Nine of 12 participants met the investigators’ definitions for both response and remission, and 10 had at least a 15-point reduction.
Those are within-group changes, not treatment-versus-control effects. They should not be compared as though they establish superiority to EMDR, Cognitive Processing Therapy, Prolonged Exposure or another established trauma-focused treatment.
Safety findings need the sample boundary
No serious adverse events were reported. The public study-related adverse-event file contains 32 records among 11 of 12 participants: 27 mild and five moderate. Headache was the most frequent event; anxiety, dizziness and several other events were also recorded. Transient monitored increases in heart rate and blood pressure occurred without a reported serious physiological event.
The sample was highly selected. From 668 completed eligibility screeners, 12 people received treatment. The study excluded several groups whose risks matter in ordinary care, including people with acute suicide risk, important cardiovascular concerns, psychosis or bipolar vulnerability, epilepsy, recent moderate or severe substance-use disorder, and some medication circumstances. Safety findings from this pilot therefore cannot be generalized to the broader veteran PTSD population.
What changes—and what does not
The publication replaces a narrow “no published treatment data” statement with one small uncontrolled dataset. It supports larger randomized, controlled and longer-term research. It does not establish efficacy, routine safety, comparative benefit, FDA approval, or a clinical recommendation.
The study also does not test psilocybin combined with EMDR. Veterans seeking care now still have access to established trauma-focused psychotherapies identified by VA, including EMDR, Cognitive Processing Therapy and Prolonged Exposure.
Frequently asked questions
How many veterans participated?
Twelve received both dosing sessions and completed the one-month primary endpoint. The planned enrollment was 15, but recruitment stopped because of budget constraints.
Were there serious adverse events?
None were reported in this small, heavily screened sample. Eleven participants had at least one study-related adverse-event record.
How intensive was the protocol?
It included roughly 14 to 16 hours of preparation and integration, plus two full dosing days with two guides and medical monitoring.
Was EMDR part of the study?
No. The study did not test EMDR, compare psilocybin with EMDR, or evaluate a combined protocol.
